Meeting
2014 ASCO Annual Meeting
An international, multicenter, randomized, double-blind phase III study of maintenance belagenpumatucel-l in non-small cell lung cancer (NSCLC): Updated analysis of patients enrolled within 12 weeks of completion of chemotherapy.
Authors
Lyudmila Bazhenova
UC San Diego Moores Cancer Center, La Jolla, CA
Lyudmila Bazhenova , Giuseppe Giaccone , John J. Nemunaitis , Erzsébet Juhász , Rodryg Ramlau , Michel M van den Heuvel , Rohit Lal , David Dunlop , Edward B. Garon , Quincy S. Chu , Minish Mahendra Jain , Ewa Carrier , Steven Moses , Daniel Shawler , Habib Fakhrai
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer - Non-Small Cell Metastatic
Track
Lung Cancer
Sub Track
Metastatic Non–Small Cell Lung Cancer
Clinical Trial Registration Number
00676507
Citation
J Clin Oncol 32:5s, 2014 (suppl; abstr 8056)
DOI
10.1200/jco.2014.32.15_suppl.8056
Abstract #
8056
Poster Bd #
237
Abstract Disclosures
Similar Posters
Poster
2014 ASCO Annual Meeting
NCIC CTG BR.26: A phase III randomized, double blind, placebo controlled trial of dacomitinib versus placebo in patients with advanced/metastatic non-small cell lung cancer (NSCLC) who received prior chemotherapy and an EGFR TKI.
First Author: Peter Michael Ellis
Poster
2019 ASCO Annual Meeting
Personalized peptide vaccination for castration-resistant prostate cancer progressing after docetaxel chemotherapy: A randomized, double-blind, placebo-controlled, phase III trial.
First Author: Masanori Noguchi
Poster
2016 ASCO Annual Meeting
A multicenter, randomized, double-blind, placebo-controlled phase III study of monosialoganglioside (GM1) preventing neurotoxicity induced by cisplatin-based chemotherapy in non-small cell lung cancer patients.
First Author: Li Zhang
Poster
2014 ASCO Annual Meeting
Tivantinib plus erlotinib versus placebo plus erlotinib in Asian patients with previously treated nonsquamous NSCLC with wild-type EGFR: First report of a phase III ATTENTION trial.
First Author: Koichi Azuma